This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by DeCrée, J. Articles by Verhaegen, H. Search for Related Content PubMed PubMed Citation Articles by DeCrée, J. Articles by Verhaegen, H. Social Bookmarking                         What's this?

The Antihypertensive and Cardiac Hemodynamic Effects of Nebivolol

From the Clinical Research Unit, St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

P. Van Rooy

From the Clinical Research Unit, St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

H. Geukens

From the Clinical Research Unit, St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

K. Haeverans

From the Clinical Research Unit, St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

H. Verhaegen

From the Clinical Research Unit, St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

Acute, subacute, and chronic treatment with nebivolol, a novel ß₁-selective adrenergic antagonist, significantly lowered systolic and diastolic blood pressure and heart rate in patients with essential hypertension. No orthostatism and bradycardia were reported. A comparison between a normal control group and 23 hypertensive patients revealed that the ratio between the preejection period (PEP) and the left ventricular ejection time (LVET) of the systolic time inter vals (STI) was significantly increased in the hypertensive patients, owing to a prolongation of the PEP_c (PEP corrected for heart rate). Treatment with ne bivolol 5 mg once a day significantly improved the PEP/LVET, in acute condi tions from 0.42 ± 0.023 to 0.39±0.018, after one month of treatment from 0.40 ± 0.013 to 0.36 ± 0.013 and after one year of treatment from 0.41 ± 0.012 to 0.36 ± 0.010, owing to a significant shortening of the PEP _c. There was no correlation between changes of blood pressure and changes of STI.

Diastolic dysfunction is an early finding in hypertension and may well be reflected in the prolongation of the PEP_c. The improvement of left ventricu lar performance, as measured with STI, suggests that treatment with nebivolol may favorably influence the underlying diastolic dysfunction and be of therapeutic value for hypertensive patients with left ventricular damage.

Angiology, Vol. 43, No. 5, 369-377 (1992)
DOI: 10.1177/000331979204300501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?